Metabolic dysfunction-associated steatotic liver disease
As the prevalence of obesity increases globally, the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) also increases in both developed and developing countries. However, the MASLD phenotype remains unclear, with many unknown reasons. Since Ludwig and others coined the te...
Saved in:
Main Authors: | Chieh Chen, Da-Ming Liao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | Tungs’ Medical Journal |
Subjects: | |
Online Access: | https://doi.org/10.4103/ETMJ.ETMJ-D-24-00019 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01) -
Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01) -
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01) -
Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01) -
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
by: Mário Reis Álvares-da-Silva, et al.
Published: (2025-01-01)